Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
World Conference on Lung Cancer (WCLC)
WCLC 2016
WCLC 2016
Plenary Session 2B: Tobacco Control and Smoking Cessation and Prevention
WCLC 2016
Tobacco use is a preventable cause of cancer. Data suggest that approximately 33% of all cancers, including lung, head and neck, esophageal, pancreas, colon, and some types of leukemia, are caused by tobacco use. This session will review the relationships between smoking, free trade, industry regulation, and global public health.
Read More ›
Noninvasive Testing for Early-Stage Lung Cancer Chemoprevention Therapy
WCLC 2016
Rates of early detection of lung cancer remain poor. Identification of endobronchial lung dysplasia with a noninvasive sputum-based test could facilitate chemoprevention. Researchers evaluated a novel test for early-stage lung cancer to determine if it can identify tumor cells that have been exfoliated into sputum.
Read More ›
Cost-Effectiveness Comparison of Screening Options for Lung Cancer Based on Randomized Population Trials
WCLC 2016
Based on data from the National Lung Screening Trial comparing lung cancer mortality associated with computed tomography (CT) and chest x-ray screening, CT screening is now standard clinical practice. However, questions about the value of CT screening remain given its cost and risk of false-positive results.
Read More ›
Atezolizumab as First-Line Therapy for Advanced NSCLC in PD-L1–Selected Patients (BIRCH)
WCLC 2016
Atezolizumab, a humanized anti–PD-L1 monoclonal antibody, is being assessed in a phase 2 study in PD-L1–selected advanced non–small-cell lung cancer (NSCLC) patients. Initial analysis demonstrated a meaningful objective response rate with durable response in chemotherapy-naive first-line and relapsed PD-L1–selected patients. Researchers reported updated efficacy data in these first-line patients.
Read More ›
Pembrolizumab in Patients with Extensive-Stage Small-Cell Lung Cancer (SCLC): KEYNOTE-028
WCLC 2016
Extensive-stage disease (ED) small-cell lung cancer (SCLC) is characterized by limited treatment options and poor survival after platinum-based chemotherapy. Pembrolizumab, an inhibitor of PD-1, is active and safe in multiple solid tumors. Researchers presented updated safety and efficacy data for patients with ED SCLC who enrolled in KEYNOTE-028.
Read More ›
First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC (CheckMate 012)
WCLC 2016
Nivolumab, a PD-1 immune checkpoint inhibitor, has demonstrated superior efficacy relative to docetaxel in patients with advanced non–small-cell lung cancer (NSCLC) who progressed on or after platinum-based chemotherapy regardless of PD-L1 expression. Researchers presented findings from a phase 1 study of nivolumab as first-line therapy for advanced NSCLC.
Read More ›
Plenary Session 5: Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer—Translational Lung Cancer Research
WCLC 2016
Association of a survival benefit with chemotherapy use for non–small-cell lung cancer (NSCLC) was observed only after the development of cisplatin and platinum doublets. Recent therapeutic advancements in NSCLC and other solid tumors have revolved around the development of immunotherapies that inhibit immune checkpoints, as well as drugs that target driver mutations.
Read More ›
Plenary Session 4A: Advances in Therapy for Metastatic Non–Small-Cell Lung Cancer (NSCLC)
WCLC 2016
This plenary session includes 4 presentations that describe the role of PD-L1 testing and immuno-oncology agents in the treatment of patients with first-line and relapsed NSCLC. All of these abstracts are embargoed until December 7, 2016.
Read More ›
Mini Oral Session 1: Improvement and Implementation of Lung Cancer Screening
WCLC 2016
Early detection of lung cancer enhances patient survival. However, the value of specific screening programs is affected by multiple factors, including patient selection methods, triage algorithms, and imaging technology. This oral session includes presentations of novel approaches to the detection of lung cancer.
Read More ›
Page 2 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us